Organisation

STRONG PARTNERSHIPS PROVIDE A SOLID FOUNDATION FOR THE DEVELOPMENT OF ARFOLITIXORIN

Isofol has established a comprehensive network with expertise in fields such as oncological research, clinical studies, manufacturing, patent issues, and commercialization. Together, these partnerships create favorable conditions for advancing the development of arfolitixorin.

Isofol is led by individuals with extensive experience in pharmaceutical and business development. The company operates in a cost-effective manner, utilizing a well-established network of leading experts in the field who are engaged on a consultancy basis. This approach provides Isofol access to essential expertise in areas including research, production (CMC), quality assurance (QA), patent matters, clinical drug development and business development.
With support from highly competent, quality-focused, and flexible partners, active knowledge exchange in external networks, and collaborations with academic institutions, the work to improve current cancer treatments continues.

Board and management

The Board of Directors consists of Chairman Jan-Eric Österlund and members Dr. Alain Herrera, Dr. Helena Taflin, Lars Lind, and Professor Sten Nilsson. Several board members have been involved in earlier phases of the company’s development and combine medical expertise with deep knowledge of business development. In addition to the Chief Executive Officer, Petter Segelman Lindqvist, the management team comprised by Dr. Roger Tell as the Chief Medical Officer and Margareta Hagman as Chief Financial Officer.

Last updated 04-11-2025